18 results with keyword: 'mechanisms therapeutic targeting mutations relapsed acute lymphoblastic leukemia'
sensitization to 6-MP therapy upon addition of HTP_2 suggesting that this phenotype is directly related to NT5C2 activity and that HTP_2 is a specific inhibitor of NT5C2 (Figure
N/A
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia..
N/A
However, emigration is accelerating this process — over the past fifteen years, people of the most fertile age (20—29) accounted for most emigrations. 3) The effect of
N/A
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
N/A
Abbreviations: N-R, Survivors of non-relapsed childhood cancer; R, Survivors of relapsed childhood cancer; ALL, acute lymphoblastic leukemia; SF-36, Short Form-36; HRQOL,
N/A
Abbreviations: ALL, acute lymphoblastic leukemia; BiD, twice a day; CCyR, complete cytogenetic response; CHR, complete hematologic response; CML, chronic
N/A
Abbreviations: N-R, Survivors of non-relapsed childhood cancer; R, Survivors of relapsed childhood cancer; ALL, acute lymphoblastic leukemia; SF-36, Short Form-36; HRQOL,
N/A
Blinatumomab can induce molecular remission in pediatric patients with posttransplant relapsed B-precursor acute lymphoblastic leukemia and facilitate subsequent
N/A
ALL: Acute lymphoblastic leukemia; T-ALL: T-cell acute lymphoblastic leukemia; B-ALL: B-cell acute lymphoblastic leukemia; MRD: Minimal residual disease; PR: Prednisone response;
N/A
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following
N/A
Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following
N/A
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia- positive acute lymphoblastic leukemia
N/A
HL60 (acute promyelocytic leukemia), MOLT-4 (acute lymphoblastic leukemia) and CCRF-CEM (acute lymphoblastic leukemia), BEAS (normal human bronchial epithelium) and HUVEC
N/A
Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
N/A
Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant..
N/A
The emissions are projected to increase significantly: According to the third IMO GHG study (IMO 2014), the emissions are ex pected to increase by 50 to 250% in the
N/A
ALL: Acute lymphoblastic leukemia; AML: Acute myelocytic leukemia; BCP- ALL: B-cell precursor acute lymphoblastic leukemia; BLK: B lymphocyte kinase; BTK: Bruton ’ s tyrosine
N/A
Previous trials of sero- therapy with various monoclonal anti- bodies in patients with multiply relapsed acute lymphoblastic leukemia (ALL) or lymphoma have
N/A